Tuberculosis Therapeutics: Past Achievements, Present Road-Blocks and Future Perspectives

Author(s): Sanjay K. Garg, Marilina B. Santucci, Fouad Seghrouchni, Cesare Saltini, Prakash S. Bisen, Vittorio Colizzi, Maurizio Fraziano

Journal Name: Letters in Drug Design & Discovery

Volume 1 , Issue 4 , 2004

Become EABM
Become Reviewer


Tuberculosis represents the main cause of mortality due to a single pathogen infection. Advances in anti-tuberculosis therapies are urgently required both for treatment of the 8-12 million new cases of tuberculosis leading to 2 million deaths each year, as well as for the 2 billion individuals already infected with M. tuberculosis, who are at the risk of developing disease. The present review summarizes the actually available information about currently existing therapies and perspectives for future innovative therapeutic approaches.

Keywords: tuberculosis, mycobacteria, therapeutics, immune-modulators

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [314 - 328]
Pages: 15
DOI: 10.2174/1570180043398515
Price: $65

Article Metrics

PDF: 2